Cargando…

21. Efficacy and Safety of Maribavir as a Rescue Treatment for Investigator Assigned Therapy in Transplant Recipients With Refractory or Resistant Cytomegalovirus Infections in the SOLSTICE Study: Phase 3 Trial Results

BACKGROUND: Refractory or resistant (R/R) cytomegalovirus (CMV) infection after hematopoietic cell transplant (HCT) and solid organ transplant (SOT) cause serious, potentially fatal complications; therapeutic options are limited. In a Phase 3 study (NCT02931539), maribavir (MBV) was superior to inve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pereira, Marcus, Cervera, Carlos, Kotton, Camille, Sasadeusz, Joseph, Wu, Jingyang, Fournier, Martha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Oral Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644079/ http://dx.doi.org/10.1093/ofid/ofab466.021

Ejemplares similares

Evaluating the Safety of Maribavir for the Treatment of Cytomegalovirus
por: Gandhi, Ronak G, et al.
Publicado: (2022)

S294: MARIBAVIR (MBV) VERSUS INVESTIGATOR-ASSIGNED THERAPY FOR REFRACTORY CYTOMEGALOVIRUS (CMV) INFECTION: SUBGROUPS ANALYSES OF PHASE 3 STUDY BY RESISTANCE STATUS KNOWLEDGE REPORTED BY INVESTIGATORS.
por: Duarte, Rafael F, et al.
Publicado: (2023)

Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study
por: Papanicolaou, Genovefa A, et al.
Publicado: (2019)

Fast selection of maribavir resistant cytomegalovirus in a bone marrow transplant recipient
por: Schubert, Axel, et al.
Publicado: (2013)

Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial( )
por: Avery, Robin K, et al.
Publicado: (2021)

Infection in Renal Transplant Recipients
por: Kotton, Camille Nelson, et al.
Publicado: (2010)

Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection
por: Chou, Sunwen, et al.
Publicado: (2020)

Maribavir for Cytomegalovirus Treatment in the Real World—Not a Silver Bullet
por: Fung, Monica, et al.
Publicado: (2022)

New Insights on CMV Management in Solid Organ Transplant Patients: Prevention, Treatment, and Management of Resistant/Refractory Disease
por: Kotton, Camille Nelson, et al.
Publicado: (2022)

A Call for Caution in the Immunocompromised: Coronavirus Disease 2019 Associated With Mortality in a Vaccinated Lung Transplant Recipient
por: Hogan, John I, et al.
Publicado: (2021)

Population pharmacokinetic modeling and simulation of maribavir to support dose selection and regulatory approval in adolescents with posttransplant refractory cytomegalovirus
por: Sun, Kefeng, et al.
Publicado: (2023)

The effects of maribavir on the autophosphorylation of ganciclovir resistant mutants of the cytomegalovirus UL97 protein
por: Shannon-Lowe, Claire D, et al.
Publicado: (2010)

2719. Oral Antibiotics for Treatment of Gram-Negative Bacteremia in Solid Organ Transplant Recipients: A Propensity Score Weighted Retrospective Observational Study
por: Nussbaum, Eliezer Zachary, et al.
Publicado: (2023)

Correction to: Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial
Publicado: (2023)

Evaluation of the Effect of Maribavir on Cardiac Repolarization in Healthy Participants: Thorough QT/QTc Study
por: Ilic, Katarina, et al.
Publicado: (2020)

Immunizations in Chronic Kidney Disease and Kidney Transplantation
por: Babu, Tara M., et al.
Publicado: (2021)

Detection of Low Frequency Multi-Drug Resistance and Novel Putative Maribavir Resistance in Immunocompromised Pediatric Patients with Cytomegalovirus
por: Houldcroft, Charlotte J., et al.
Publicado: (2016)

Summer Solstice 2013 International Conference on Discrete Models of Complex Systems
por: Krawiecki, Andrzej
Publicado: (2013)

Maribavir Pharmacokinetics and Safety in Participants With Moderate Hepatic Impairment: A Phase 1, Open‐Label, Single‐Dose, Parallel Group Study
por: Song, Ivy, et al.
Publicado: (2022)

Widely rhythmic transcriptome in Calanus finmarchicus during the high Arctic summer solstice period
por: Payton, Laura, et al.
Publicado: (2020)

Daily transcriptomes of the copepod Calanus finmarchicus during the summer solstice at high Arctic latitudes
por: Payton, Laura, et al.
Publicado: (2020)

Synthesis of New Imidazopyridine Nucleoside Derivatives Designed as Maribavir Analogues
por: Papadakis, Georgios, et al.
Publicado: (2020)

Conserved retinoblastoma protein-binding motif in human cytomegalovirus UL97 kinase minimally impacts viral replication but affects susceptibility to maribavir
por: Gill, Rachel B, et al.
Publicado: (2009)

Placental transfer of Letermovir & Maribavir in the ex vivo human cotyledon perfusion model. New perspectives for in utero treatment of congenital cytomegalovirus infection
por: Faure Bardon, Valentine, et al.
Publicado: (2020)

Evidence for oscillating circadian clock genes in the copepod Calanus finmarchicus during the summer solstice in the high Arctic
por: Hüppe, Lukas, et al.
Publicado: (2020)

1531. A CMV Vaccine Based on Non-Replicating Lymphocytic Choriomeningitis Virus Vectors Expressing gB and pp65 Is Safe and Immunogenic in Healthy Volunteers, Allowing for Development of a Phase II Clinical Trial in Living Donor Kidney Transplant Recipients
por: Kotton, Camille Nelson, et al.
Publicado: (2018)

Effects of Maribavir on P‐Glycoprotein and CYP2D6 in Healthy Volunteers
por: Song, Ivy H., et al.
Publicado: (2019)

Rhodococcus Infection in Solid Organ and Hematopoietic Stem Cell Transplant Recipients
por: Vergidis, Pascalis, et al.
Publicado: (2017)

Spectrum of Coronavirus Disease 2019 Outcomes in Kidney Transplant Recipients: A Single-Center Experience
por: Lum, Erik, et al.
Publicado: (2020)

20. Risk Factors for Breakthrough Cytomegalovirus (CMV) Infection and De Novo Resistance in Hematopoietic Cell Transplantation (HCT) Recipients Receiving Letermovir Prophylaxis
por: Zamora, Danniel, et al.
Publicado: (2021)

2715. Toxicities and clinical consequences of valganciclovir prophylaxis in solid organ transplant recipients
por: Lahoud, Chloe, et al.
Publicado: (2023)

Cytomegalovirus in the transplant setting: Where are we now and what happens next? A report from the International CMV Symposium 2021
por: Kotton, Camille N., et al.
Publicado: (2022)

Ultra-thin strut cobalt chromium bare metal stent usage in a complex real-world setting. (SOLSTICE registry)
por: Suttorp, M. J., et al.
Publicado: (2015)

1060. Pritelivir in Immunocompromised Patients with Mucocutaneous Acyclovir-Resistant Herpes Simplex Virus-Infections – First Case Series
por: Albrecht, Kim WorkowskiJoerg, et al.
Publicado: (2021)

Assessment of UL56 Mutations before Letermovir Therapy in Refractory Cytomegalovirus Transplant Recipients
por: Santos Bravo, Marta, et al.
Publicado: (2022)

The Cytomegalovirus-Specific IL-21 ELISpot Correlates with Allograft Function of Kidney Transplant Recipients
por: Lindemann, Monika, et al.
Publicado: (2018)

Editorial: Progenitors and Stem Cells in Thyroid Development, Disease, and Regeneration
por: Kotton, Darrell N., et al.
Publicado: (2022)

Liver Transplantation for Recurrent Cholangitis From Von Meyenburg Complexes
por: Panda, Nikhil, et al.
Publicado: (2019)

Assignment of protonation states and geometries to macromolecular structures using Unary Quadratic Optimization
por: Labute, Paul
Publicado: (2008)

Cytomegalovirus infections in the blood recipient.
por: Nankervis, G. A.
Publicado: (1976)

Cannot write session to /tmp/vufind_sessions/sess_75g633hlopl4b3b2g42hmqtffr